Profhilo

What is PROFHILO?

Profhilo is the first BDDE-free stabilised injectable hyaluronic acid (HA) based product for treating skin laxity. With one of the highest concentrations of HA on the market (64mg / 2ml) it is not only boosting and hydrating the skin, but also remodels the ageing and sagging tissue. Profhilo delivers great results as a treatment on its own or in combination with other aesthetics treatments currently on offer.

Exciting development

Profhilo is creating a real buzz ,  aesthetic practitioners are referring to it “as something they have been waiting for” or as “the most exciting development in injectable treatments in a long time”.

HOW DOES PROFHILO WORK?
  1. As a stabilised product Profhilo lasts in the skin around 28 days. During this time the stimulation of 4 different types of collagen and elastin takes place by slow release of HA.
  2. The stimulation results in significant tissue improvement. Therefore we cannot say that Profhilo is a skin booster as it also has a significant tightening / lifting effect on the tissue.

UNIQUE PRODUCT

There are many characteristics that make Profhilo unique from anything else available on the market right now. There is no BDDE content. It is thermally cross-linked generating stabilised hybrid co-operative complexes of H-HA and L-HA. Despite its high HA content, it has a low inflammatory profile coupled with pro-healing properties backed by clinical studies. To fully understand this new concept in anti-ageing medicine we have to take a look at the technology first.

HOW IS PROFHILO STABILISED?

Profhilo is developed by using a patented technology resulting in hybrid cooperative complexes between high molecular weight HA and low molecular HA without the use of any chemical cross-linking compounds. These complexes increase the stability of HA to enzymatic and mechanical degradation.

  • NAHYCO TECHNOLOGY

Profhilo is not a dermal filler or biorevitaliser – Profhilo has opened up a new injectable category – bioremodeling. Thermal cross-linking changes the character and behavior of the HA resulting in the formation of co-operative hybrid complexes which modulate the tissues. This is also the explanation for the different biological behavior with respect to H-HA and L-HA alone. One of the main advantages is longevity. Hybrid cooperative complexes have proven to be very stable with natural hyaluronidase (BTH) digestion when compared to H-HA, widely used in biorevitalisation products, or L-HA alone resulting in the long-lasting release and the dual action of the two HA components. This dual action is ideal for remodeling skin laxity.

  • ADVANTAGES

In Profhilo, L-HA is released slowly from the HA hybrid complexes and therefore does not trigger the first inflammatory cytokines making it very biocompatible. It also increas¬es patient comfort during and after treatment and provides hydration to the skin especially in the epidermis – the Hydro effect.
H-HA in Profhilo provides a stable HA architecture in the dermis. This gives a volumetric effect – the Lift effect.
Another advantage of the stable co-operative hybrid complex when compared to H-HA and L-HA is the increase in the ex¬pression levels of type I and type III collagen in fibroblast and type IV and VII collagen in keratinocytes.
This results in improved skin quality and skin hydration both in the dermis and epidermis. There is also increased production of endogenous HA and elastin giving the skin a more youthful look.

  • HIGHEST CONCENTRATION ON THE MARKET

Profhilo contains 32mg of low molecular weight HA (80-100Kda) and 32 mg of high molecular weight HA (1100-1400Kda). This gives one of the highest concentration of HA on the market totalling 64 mg of HA in a 2ml prefilled syringe. Remarkably this can still be extruded using a 29g needle.

  • BAP TECHNIQUE

o maximise the diffusion in the malar and sub-malar areas:

• The BAP were specifically chosen in anatomically respective areas
• The dilution phenomenon of the product itself
• 5 injections per side
• Reduced pain (slow injection)
• Lower possibility of bruising or hematoma
• Reduced number of treatment sessions
• Greater patient compliance